Prelude Therapeutics Incorporated logo
Prelude Therapeutics Incorporated PRLD
$ 5.55 3.54%
report update icon

Quarterly report 2026-Q2
added 08-11-2026

Prelude Therapeutics Incorporated Financial Ratios 2025-2011 | PRLD

Annual Financial Ratios Prelude Therapeutics Incorporated

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-2.8 -2.1 -1.7 -2.7 -3.6 -3.6 - - - - - - - - -

P/S

22.8 39.0 - - - - - - - - - - - - -

EPS

-1.3 -1.7 -2.0 -2.4 -2.4 -4.6 -16.5 - - - - - - - -

EV (Enterprise Value)

314 M 304 M 226 M 300 M 394 M 579 K 71.3 M 39.1 M - - - - - - -

EBITDA per Share

-1.34 -1.82 -2.17 -2.58 -2.45 -18.2 - - - - - - - - -

EV/EBITDA

-3.1 -2.2 -1.7 -2.5 -3.2 0.2 - - - - - - - - -

PEG

0.1 - - - - 0.03 - - - - - - - - -

P/B

4.0 2.1 0.9 1.6 1.4 1.0 - - - - - - - - -

P/CF

-4.9 -2.7 -2.0 -3.7 -4.9 -4.4 - - - - - - - - -

ROE %

-144.97 -96.74 -51.39 -59.07 -39.07 -26.83 - - - - - - - - -

ROA %

-70.41 -72.46 -43.88 -52.35 -36.61 -25.46 - - - - - - - - -

ROCE %

-152.35 -106.28 -55.79 -63.21 -39.78 -27.69 - - - - - - - - -

Current Ratio

1.9 4.0 6.8 8.8 15.9 19.4 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Prelude Therapeutics Incorporated

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.41 -0.13 - -0.26 -0.41 -0.42 - -0.43 -0.46 -0.42 - -0.45 -0.54 -0.58 - -0.63 -0.58 -0.63 - -0.66 -0.58 -0.47 - -5.25 -5.5 -5.12 - -3.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.42 -0.17 - - - -0.45 - - - -0.45 - - - -0.6 - -0.62 -0.61 -0.64 - -0.65 -0.6 -0.48 - -5.55 -5.38 -5.17 - -3.87 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-116.54 -123.23 -105.98 -126.61 -111.97 -85.70 -54.60 -67.45 -58.43 -55.19 -40.27 -54.05 -52.57 -52.21 -36.40 -46.26 -40.51 -35.12 -23.87 -31.77 -27.28 -23.73 -17.76 -4.13 20.47 44.67 49.15 13.63 16.70 18.82 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-79.38 -79.39 -70.71 -87.07 -81.74 -67.28 -44.57 -56.41 -50.89 -49.38 -36.66 -49.02 -47.75 -47.40 -33.43 -42.69 -38.01 -33.21 -22.71 -30.21 -26.04 -22.61 -16.85 -47.64 -5.10 -4.25 - -30.79 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-125.38 -134.43 -110.87 -132.85 -118.36 -92.20 -58.66 -72.67 -63.06 -59.28 -42.98 -56.97 -55.19 -54.40 -37.79 -47.69 -42.06 -35.99 -24.42 -32.97 -28.45 -24.69 -18.53 -4.60 -5.39 -4.59 - 13.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.9 2.0 4.0 2.6 2.9 3.7 6.8 4.8 5.3 6.8 8.8 12.8 15.1 8.6 - 9.7 14.2 14.9 15.9 16.6 23.0 27.9 19.6 19.6 19.6 19.6 4.5 4.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Prelude Therapeutics Incorporated, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada